Outcomes for Pembrolizumab Stratified by Pemetrexed Maintenance Post Pembrolizumab–Platinum–Pemetrexed Induction in Metastatic Non-Small-Cell Lung Cancer

References

• Abernethy AP, Arunachalam A, Burke T et al. Real-world first-line treatment and overall survival in non-small-cell lung cancer without known EGFR mutations or ALK rearrangements in US community oncology setting. PLOS ONE 12(6), e0178420 (2017).
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, de Marinis F, Dediu M et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer (PARAMOUNT): a double-blind, Phase III, randomised controlled trial. Lancet Oncol. 13(3), 247–255 (2012).
   PubMed Web of Science ®Google Scholar
• Brodowicz T, Krzakowski M, Zwitter M et al. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small-cell lung cancer: a Phase III trial. Lung Cancer 52(2), 155–163 (2006).
   PubMed Web of Science ®Google Scholar
• Ciuleanu T, Brodowicz T, Zielinski C et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, Phase III study. Lancet 374(9699), 1432–1440 (2009).
   PubMed Web of Science ®Google Scholar
• Fidias PM, Dakhil SR, Lyss AP et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J. Clin. Oncol. 27(4), 591–598 (2009).
   PubMed Web of Science ®Google Scholar
• Paz-Ares LG, de Marinis F, Dediu M et al. PARAMOUNT: final overall survival results of the Phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J. Clin. Oncol. 31(23), 2895–2902 (2013).
   PubMed Web of Science ®Google Scholar
• Borghaei H, Paz-Ares L, Horn L et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 373(17), 1627–1639 (2015).
   PubMed Web of Science ®Google Scholar
• Garassino MC, Cho BC, Kim JH et al. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, Phase II study. Lancet Oncol. 19(4), 521–536 (2018).
   PubMed Web of Science ®Google Scholar
• Reck M, Rodríguez-Abreu D, Robinson AG et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N. Engl. J. Med. 375(19), 1823–1833 (2016).
   PubMed Web of Science ®Google Scholar
• West H, McCleod M, Hussein M et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic nonsquamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, Phase III trial. Lancet Oncol. 20(7), 924–937 (2019).
   PubMed Web of Science ®Google Scholar
• Gandhi L, Rodríguez-Abreu D, Gadgeel S et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N. Engl. J. Med. 378(22), 2078–2092 (2018).
   PubMed Web of Science ®Google Scholar
• Gadgeel S, Rodríguez-Abreu D, Speranza G et al. Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer. J. Clin. Oncol. 38(14), 1505–1517 (2020).
   PubMed Web of Science ®Google Scholar
• Kim SY, Halmos B. Choosing the best first-line therapy: NSCLC with no actionable oncogenic driver. Lung Cancer Manag. 9(3), LMT36 (2020).
   PubMedGoogle Scholar
• Reck M, Ciuleanu TE, Cobo M et al. First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: checkMate 9LA 2-year update. ESMO Open 6(5), 100273 (2021).
   PubMed Web of Science ®Google Scholar
• Bayo K, Aggarwal H, Han Y, Muehlenbein C, Zhu YE, Kim JS. Real world data on maintenance therapy utilization and overall survival among advanced non-small-cell lung cancer patients treated with pemetrexed in combination with pembrolizumab and platinum chemotherapy in the US. J. Thorac. Oncol. 16(Suppl. 1), S38 (2020).
   Web of Science ®Google Scholar
• Velcheti V, Hu X, Piperdi B, Burke T. Real-world outcomes of first-line pembrolizumab plus pemetrexed-carboplatin for metastatic nonsquamous NSCLC at US oncology practices. Sci. Rep. 11(1), 9222 (2021).
   PubMed Web of Science ®Google Scholar
• Aggarwal H, Bayo K, Han Y, Muehlenbein CE, Zhu YE, Kim JS. Real-world maintenance therapy and survival outcomes for pembrolizumab plus pemetrexed and platinum for non-small-cell lung cancer in USA. Immunotherapy 15(4), 267–281 (2023).
   PubMedGoogle Scholar
• The US Oncology Network. www.usoncology.com/our-company
   Google Scholar
• Boyd M, Fulcher N, Annavarapu S et al. PCN1 Concordance of death date assessments between the Social Security Death Master File and electronic health records in a US community oncology setting. Value Health 23(Suppl. 1), S22 (2020).
   Google Scholar
• Griffin BA, Ridgeway G, Morral AR et al. Toolkit for Weighting and Analysis of Nonequivalent Groups (TWANG). RAND Corporation. CA, USA (2014). www.rand.org/statistics/twang.html
   Google Scholar
• International Society for Pharmacoepidemiology. Guidelines for Good Pharmacoepidemiology Practices (GPP) (June 2015). www.pharmacoepi.org/resources/policies/guidelines-08027/
   Google Scholar
• Rodríguez-Abreu D, Powell SF, Hochmair MJ et al. Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189. Ann. Oncol. 32(7), 881–895 (2021).
   PubMed Web of Science ®Google Scholar
• Garassino MC, Gadgeel S, Speranza G et al. Pembrolizumab plus pemetrexed and platinum in nonsquamous non-small-cell lung cancer: 5-year outcomes from the Phase III KEYNOTE-189 study. J. Clin. Oncol. 41(11), 1992–1998 (2023).
   PubMed Web of Science ®Google Scholar
• Kato R, Hayashi H, Chiba Y et al. Propensity score-weighted analysis of chemotherapy after PD-1 inhibitors versus chemotherapy alone in patients with non-small-cell lung cancer (WJOG10217L). J. Immunother. Cancer 8(1), e000350 (2020).
   PubMed Web of Science ®Google Scholar